Articles published by Turn Therapeutics

Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors

January 07, 2026

From Turn Therapeutics

Via GlobeNewswire

Tickers TTRX

Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

November 13, 2025

From Turn Therapeutics

Via GlobeNewswire

Tickers TTRX

Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine

November 11, 2025

From Turn Therapeutics

Via GlobeNewswire

Tickers TTRX

Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D.

November 11, 2025

From Turn Therapeutics

Via GlobeNewswire

Tickers TTRX

Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications

November 04, 2025

From Turn Therapeutics

Via GlobeNewswire

Tickers TTRX

Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline

October 30, 2025

From Turn Therapeutics

Via GlobeNewswire

Tickers TTRX

Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones

October 22, 2025

From Turn Therapeutics

Via GlobeNewswire

Tickers TTRX

Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025

October 20, 2025

From Turn Therapeutics

Via GlobeNewswire

Tickers TTRX

Turn Therapeutics Appoints Dr. Kent Kester to Board of Directors

October 15, 2025

From Turn Therapeutics

Via GlobeNewswire

Tickers TTRX

Turn Therapeutics Appoints Arthur Golden to Board of Directors

October 14, 2025

From Turn Therapeutics

Via GlobeNewswire

Tickers TTRX

Turn Therapeutics to Commence Trading Today on Nasdaq

October 08, 2025

From Turn Therapeutics

Via GlobeNewswire

Turn Therapeutics Announces Expected First Day of Trading on NASDAQ Global Market

September 29, 2025

From Turn Therapeutics

Via Business Wire

Turn Therapeutics to Host Open Investor Session in Connection with Expected Public Listing on Nasdaq

September 15, 2025

From Turn Therapeutics

Via Business Wire

Turn Therapeutics Intranasal Vaccine Candidate Demonstrates Extended Stability

August 06, 2025

From Turn Therapeutics

Via Business Wire

Turn Therapeutics Begins Clinical Trial of First Topical IL-36/IL-31 Inhibitor for Eczema

July 14, 2025

From Turn Therapeutics

Via Business Wire

Turn Therapeutics Announces Vaccine Breakthrough: Validates 100% VSV Recovery from Petrolatum Carrier at 24 and 72 Hours

May 02, 2025

From Turn Therapeutics

Via Business Wire

Turn Therapeutics Launches Final Crowdfund Round Ahead of Eczema Trial Enrollment, Engages Clear Street to Explore Public Markets

April 02, 2025

From Turn Therapeutics

Via Business Wire

Turn Therapeutics Achieves 24-Hour Stability for Live Vaccine in Intranasal Oil Suspension at Room Temperature, Marking Major Milestone Toward Improving Vaccine Access

February 05, 2025

From Turn Therapeutics

Via Business Wire

Turn Therapeutics Secures $75 Million Investment Commitment Tied to Public Listing

December 12, 2024

From Turn Therapeutics

Via Business Wire

Turn Therapeutics Atopic Dermatitis Candidate Reduces Disease Severity by 57% In-Vivo

June 20, 2024

From Turn Therapeutics

Via Business Wire

Turn Therapeutics invites public investment for expansion of flagship wound formula into eczema, toenail fungus

May 22, 2024

From Turn Therapeutics

Via Business Wire

Turn Therapeutics Announces Human Trial Data for COVID-19 Early Intervention Candidate

August 25, 2021

From Turn Therapeutics

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.